Adi Mor
Chief Executive Officer bij CHEMOMAB THERAPEUTICS LTD.
Vermogen: 22 132 $ op 31-03-2024
Profiel
Adi Mor is the founder.
She founded Chemomab Ltd.
in 2011, where she holds the title of Director, Chief Executive & Scientific Officer.
She also founded Chemomab Therapeutics Ltd.
in 2011, where she holds the title of Chief Executive Officer & Director.
Dr. Mor obtained a doctorate degree from Tel-Aviv University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 28-03-2024 | 568 222 ( 0.27% ) | 22 132 $ | 31-03-2024 |
Actieve functies van Adi Mor
| Bedrijven | Functie | Begin |
|---|---|---|
| CHEMOMAB THERAPEUTICS LTD. | Chief Executive Officer | 01-06-2023 |
Chemomab Ltd.
 Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | Chief Executive Officer | 01-01-2011 |
Opleiding van Adi Mor
| Tel-Aviv University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CHEMOMAB THERAPEUTICS LTD. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | Health Technology |
